Uveal melanomas can be divided into prognostically significant subgroups based on their transcriptomic signature. Class 1 tumors rarely metastasize, and they tend be less invasive, more differentiated and occur in younger individuals than class 2 tumors^[@R1]^. In contrast, class 2 tumors frequently metastasize, and they tend to comprise undifferentiated "epithelioid" tumor cells lacking a copy of chromosome 3^[@R1]^.

We recently described loss of function mutations in *BAP1* (BRCA1-associated protein 1), located at chromosome 3p21.1, in ∼40% of uveal melanomas, virtually all of which were the aggressive class 2 tumors^[@R2]^. In the present study, we searched for additional mutations in uveal melanoma by exome sequencing of 18 primary tumors, including seven class 1 and eleven class 2 tumors. Exome data were filtered down to somatic alterations that were predicted to be deleterious ([Supplementary Methods](#SD1){ref-type="supplementary-material"}). Only two genes were found to harbor deleterious somatic variants in at least three tumor samples: guanine nucleotide-binding protein G(q) subunit alpha (*GNAQ*), which is already known to undergo mutation in uveal melanoma^[@R3],[@R4]^, and splicing factor 3B subunit 1 (*SF3B1*). In the case of *SF3B1*, the mutation in all three tumors led to a p.R625C alteration (hg19 chr2:198267484G\>A) which was confirmed by Sanger sequencing.

We manually examined the entire *SF3B1* coding sequence from the other 15 exome samples, but we did not find mutations at any sites other than R625. *SF3B1* mutations were recently described in myelodysplastic syndrome (MDS) and chronic lymphocytic leukemia (CLL), clustering within exons 12 to 15^[@R5],[@R6]^. Thus, we re-sequenced these exons in a total of 102 primary uveal melanomas and matching blood DNA samples and identified *SF3B1* mutations in 19 (18.6%) tumors ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). This frequency is similar to that in MDS and CLL^[@R5],[@R6]^, and much higher than that recently reported in breast cancer^[@R7]^. Strikingly, all of the mutations in uveal melanoma occurred atarginine-625, including twelve R625H, five R625C, one R625G and one R625L substitutions ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). Interestingly, R625 is one of many sites in *SF3B1* that are mutated in MDS, but it is the only site that was identified as deleterious by the SIFT algorithm^[@R5]^, which predicts the effect an amino acid substitution has on protein function. *SF3B1* mutations were not present in matching blood DNA samples, indicating that they were somatic in origin. In each of the tumors with *SF3B1* mutations, wildtype and mutant alleles were present in roughly equal proportions ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). An evaluation of DNA copy number in 30 of the uveal melanomas, including seven with *SF3B1* mutations, revealed no loss of chromosome 2q33.1 where *SF3B1* resides ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}),which would have been consistent with a classical tumor suppressor. Rather, these findings are more consistent with *SF3B1* mutations functioning as dominant-negative, gain-of-function or haploinsufficient alteration.

*SF3B1* mutations were associated with favorable prognostic features such as younger patient age (P=0.03) and fewer undifferentiated epithelioid cells (P=0.003), and they were inversely associated with poor prognostic features such as the class 2 transcriptomic signature (P = 0.02), loss of chromosome 3 (P = 0.001) and mutation of *BAP1* (P=0.002) ([Table 1](#T1){ref-type="table"}). Patients with *SF3B1*-mutant tumors trended toward a lower metastatic rate than those with *SF3B1*-wildtype tumors (P=0.1), which was in striking contrast to the high metastatic rate in patients with *BAP1* mutations (P\<0.0001)([Fig. 1](#F1){ref-type="fig"}). Five uveal melanoma samples from distant metastases were available for testing, and none harbored *SF3B1* mutations, further supporting the notion that these mutations might be associated with less aggressive tumors. Taken together, these findings indicate that *SF3B1* mutations are associated with better prognosis in uveal melanoma, which is similar to findings in MDS^[@R5]^.

*SF3B1* is one of very few genes that are commonly mutated in uveal melanoma, allowing for a more precise molecular taxonomy of this cancer. Activating oncogenic mutations in *GNAQ* or *GNA11* occur in about 85% of primary uveal melanomas and are thought to represent early events because they are found in uveal melanomas of all stages, including pre-malignant nevi, and they are not associated with prognosis^[@R3],[@R8]^. Consistent with this idea, *GNAQ/GNA11* mutations were present in most of our *SF3B1*-mutant and *BAP1*-mutant tumors, suggesting that they arise earlier than *SF3B1* and *BAP1* mutations. In contrast, *SF3B1* and *BAP1* mutations were almost mutually exclusive, suggesting that they may represent alternative pathways in tumor progression.

*SF3B1* encodes subunit 1 of the splicing factor 3b protein complex, which is a component of the U2 small nuclear ribonucleoprotein complex (snRNP) that participates in the splicing of pre-mRNAs^[@R9]^. Splicing factor 3b is also a component of the minor U12-type spliceosome^[@R9]^. To explore the effects of mutant *SF3B1* on global RNA expression, we analyzed five *SF3B1*-mutant and six *SF3B1*-wildtype class 1 tumors for differentially expressed transcripts using the Illumina Bead Array platform. This analysis was limited to class 1 tumors because most *SF3B1* mutations occurred in this subset. Surprisingly, there were only 10 differentially expressed genes, and they provided no insights into the functional significance of the *SF3B1* mutations ([Supplementary Table 2 and Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). Moreover, none of these genes were the same as those that were differentially expressed in MDS^[@R5],[@R10]^. We therefore investigated if the main consequence of *SF3B1* mutations was intron retention rather than differential expression. Three *SF3B1*-mutant and five *SF3B1*-wildtype class 1 tumors were analyzed for alterations in splice donor and splice acceptor retention using RNA-Seq ([Supplementary Methods](#SD1){ref-type="supplementary-material"}). However, no differences in global splice donor or acceptor retention were found between *SF3B1*-mutant and --wildtype tumors (data not shown). Further, we manually analyzed a set of neural crest regulatory transcripts that are aberrantly spliced in *sf3b1*-mutant zebrafish (*SNAI1, SOX9, TFAP2A, SOX10, ID2, MITF* and *SF3B1*)^[@R11]^, but no splicing abnormalities were found. Despite the known role of *SF3B1* in RNA splicing, there have not been consistent results linking *SF3B1* mutations to specific splicing errors in MDS or CLL, and the functional consequences of *SF3B1* mutations remain elusive despite intensive investigation^[@R12]^. Recent links between *SF3B1* and chromatin remodelling complexes^[@R13]^ raise the question of whether the primary effect of *SF3B1* mutations on tumor progression involve RNA processing at all. Further investigations are under way to elucidate the effects of *SF3B1* mutations on uveal melanoma progression in order to therapeutically target these effects.
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###### Associations between *SF3B1* mutation and clinical, histopathologic and genetic features

  Variable                       *SF3B1* wildtype   *SF3B1* mutant   P-value
  ------------------------------ ------------------ ---------------- ---------
  Patient age                                                        
   Mean                          63.0               55.3             0.03
   Median                        65.0               60.0             
   Minimum, Maximum              24-87              16-76            
                                                                     
  Patient sex                                                        
   Female                        34 (41%)           12 (63%)         0.1
   Male                          49 (59%)           7 (37%)          
                                                                     
  Tumor diameter (mm)                                                
   Mean                          16.0               17.1             0.3
   Median                        16.0               17.2             
   Minimum, Maximum              3-24               9-24             
                                                                     
  Tumor thickness (mm)                                               
   Mean                          8.8                8.6              0.8
   Median                        9.0                8.1              
   Minimum, Maximum              1-16               2-15             
                                                                     
  Ciliary body involvement                                           
   Yes                           44 (60%)           9 (47%)          0.4
   No                            29 (40%)           10 (53%)         
   Not available                 10                 0                
                                                                     
  Epithelioid cell type                                              
   Yes                           33 (40%)           1 (5%)           0.003
   No                            49 (60%)           18 (95%)         
   Not available                 1                  0                
                                                                     
  Extraocular tumor invasion                                         
   Yes                           17 (21%)           5 (26%)          0.8
   No                            64 (79%)           14 (74%)         
   Not available                 2                  0                
                                                                     
  *BAP1* status                                                      
   Wildtype                      37 (54%)           16 (94%)         0.002
   Mutant                        31 (46%)           1 (6%)           
   Not available                 15                 2                
                                                                     
  *GNAQ* status                                                      
   Wildtype                      40 (60%)           10 (53%)         0.6
   Mutant                        27 (40%)           9 (47%)          
   Not available                 16                 0                
                                                                     
  *GNA11* status                                                     
   Wildtype                      28 (43%)           12 (67%)         0.1
   Mutant                        37 (57%)           6 (33%)          
   Not available                 18                 1                
                                                                     
  Gene expression class                                              
   Class 1                       37 (49%)           14 (82%)         0.02
   Class 2                       38 (51%)           3 (18%)          
   Not available                 8                  2                
                                                                     
  Chromosome 3 status                                                
   Retention of heterozygosity   34 (49%)           14 (93%)         0.001
   Loss of heterozygosity        36 (51%)           1 (7%)           
   Not available                 13                 4                
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